Christopher Sturbaum, MD
Ophthalmology · Spokane Valley, WANPI 1457361560
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson Surgical Vision, Inc. accounts for 61.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $11,303 and has fallen 95.1% since, to $557 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $157.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$18K
- Biotissue Holdings Inc.$5K
- AbbVie$3K
- Novartis$531
- Sun Pharmaceutical Industries Inc.$377
- Rxsight Inc$321
- plus $2K from 21 others
What the payments were for
- Consulting fees$15,62652%
- Speaking & faculty fees$4,32614%
- Travel & lodging$4,48815%
- Food & beverage$5,46618%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 40 | $18,270 |
| Biotissue Holdings Inc. | 15 | $5,368 |
| AbbVie(2 entities) | 28 | $3,199 |
| Novartis | 14 | $531 |
| Sun Pharmaceutical Industries Inc. | 11 | $377 |
| Rxsight Inc | 6 | $321 |
| Mallinckrodt Enterprises LLC | 9 | $243 |
| Mallinckrodt Hospital Products Inc. | 10 | $242 |
| Alcon | 10 | $185 |
| Dompe US, Inc. | 7 | $166 |
| Glaukos Corporation | 4 | $157 |
| Oyster Point Pharma, Inc. | 5 | $155 |
| Merz Pharmaceuticals, LLC | 6 | $148 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $96 |
| Tarsus Pharmaceuticals, Inc. | 3 | $60 |
| Harrow Eye, LLC | 2 | $58 |
| Aerie Pharmaceuticals, Inc. | 3 | $40 |
| Lumibird Medical Inc. | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 1 | $34 |
| Rayner Intraocular Lenses Limited | 1 | $33 |
| Shire North American Group Inc | 2 | $33 |
| Omeros Corporation | 1 | $30 |
| Bausch & Lomb Americas Inc. | 1 | $25 |
| Carl Zeiss Meditec USA, Inc. | 1 | $24 |
| Amgen | 1 | $16 |
| Ivantis, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$9,953
- RESTASIS$2,519
- Tecnis Symfony IOL$2,132
- Tecnis Multifocal Family of 1-piece IOLS$230
- TRAVATAN Z$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- XIIDRA$125
- Healon Viscoelastics$125
- Ophthalmic Surgical Adjuncts$125
- Catalys Laser System$125
- Whitestar Phacoemulsficiation System$125
- VUITY$121
- Prokera$117
- AmnioGraft$117
- XEN GLAUCOMA TREATMENT SYSTEM$117
- CEQUA$104
- BROMSITE$104
- XELPROS$104
How this compares
$29,905 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 16 | $783,859 |
| RestasisCyclosporine | 118 | $137,329 |
| Cyclosporine | 58 | $39,610 |
| LumiganBimatoprost | 36 | $19,061 |
| XiidraLifitegrast | 12 | $13,540 |
| Prednisolone Acetate | 366 | $13,512 |
| CequaCyclosporine | 11 | $11,599 |
| MieboPerfluorohexyloctane/Pf | 12 | $9,177 |
| TyrvayaVarenicline Tartrate | 12 | $7,884 |
| Ketorolac Tromethamine | 291 | $5,818 |
| Loteprednol Etabonate | 30 | $5,509 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $4,021 |
| MoxifloxacinMoxifloxacin Hcl | 98 | $3,359 |
| Alphagan PBrimonidine Tartrate | 12 | $3,005 |
| ValacyclovirValacyclovir Hcl | 34 | $2,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $166 | $783,85916 claims |
| AbbVieRestasis, Lumigan, Alphagan P | $3,199 | $159,395166 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $25 | $22,71724 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $377 | $11,59911 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $155 | $7,88412 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $96 | $5,50930 claims |
| AlconSimbrinza | $185 | $4,02112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Spokane Valley
- Mark KontosSpokane Valley$175K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.